Sorafenib has been generally shown to have an excellent anti-tumor effect in various types of cancers including HCC (Scott et al., 2004; Chang et al., 2007), whereas IQGAP1 mediated ERK activation may interfere with its therapeutic action (Hedman, Smith & Sacks, 2015). Here, IQGAP1 is linked to cancer.